GDF15 levels increase significantly in patients with obesity and normoglycemia and in those with obesity and impaired glucose tolerance or type 2 diabetes, while FGF21 concentrations significantly decrease in patients with obesity and impaired glucose tolerance or type 2 diabetes. This evidence concerns the gene FGF21 and type 2 diabetes mellitus.